Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia [NA]

View source ↗

Summary

A clinical trial update for JY231 injection in relapsed or refractory B-cell lymphomas and leukemias, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• JY231

Snippet

Sponsor: Tongji Hospital | Conditions: B-ALL, B-NHL | NA | Status: RECRUITING